Figure 5 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis
Year: 2024
Type: other
Abstract: Navitoclax enhances BTZ-induced cytotoxicity. A and B, H1975 and H460 cells were treated with vehicle or the indicated concentrations of navitoclax with/without BTZ (2 nmol/L) for 96 hours. Cell viability was determined by WST-1 assay. C, H1975-Control or H1975-p53KO cells were treated with vehicle or the indicated concentrations of navitoclax with/without BTZ (5 nmol/L) for 96 hours. Cell viability was determined by WST-1 assay. D and E, NOD-SCID-II.2 receptor gamma null (NSG) mice were injected with 3.0 × 106 H1975 (D) or 1.0 × 106 H460 cells (E), and once tumors became palpable, mice were treated for 3 weeks with vehicle (control) or the combination of BTZ (1.0 mg/kg) 2×/week via intraperitoneal injection + navitoclax (NAV; 80 mg/kg) 3×/week via oral gavage + carboplatin (CBP; 25 mg/kg) once weekly via intraperitoneal injection. The period of treatment is indicated by the horizontal bar, and tumor volumes were measured twice weekly (N = 6 mice/group). *, P < 0.05; **, P < 0.01; ***, P < 0.005; ns indicates P > 0.05. Error bars indicate ± 1.0 SD., except in D and E in which error bars indicate SEM.
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4403433454